-
公开(公告)号:WO2015033140A1
公开(公告)日:2015-03-12
申请号:PCT/GB2014/052675
申请日:2014-09-04
CPC分类号: A61K38/16 , A61K39/0011 , A61K39/39 , A61K45/06 , A61K2039/57 , A61K2039/572 , C07K14/70514 , C07K14/70517
摘要: A pharmaceutical composition comprising at least two peptides of from 20 to 60 amino acids in length, selected from peptides comprising a sequence of at least 20 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 40 and 48 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: 1 to 40 and 48, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope.
摘要翻译: 一种包含长度为20至60个氨基酸的至少两个肽的药物组合物,其选自包含SEQ ID NO:1至40和48所示序列之一至少20个连续氨基酸的序列的肽,或 与SEQ ID NO:1至40和48所示的序列之一具有至少80%同一性的序列,其中每个肽包含至少一个CD8 + T细胞表位和/或至少一个CD4 + T细胞表位。
-
公开(公告)号:WO2012090002A1
公开(公告)日:2012-07-05
申请号:PCT/GB2011/001781
申请日:2011-12-30
申请人: IMMUNE TARGETING SYSTEMS (ITS) LTD , BROWN, Carlton Bradley , GEORGES, Bertrand Victor Gilbert , THABURET, Jean Francois
IPC分类号: A61K39/145 , A61K39/00 , A61K39/385
CPC分类号: A61K39/145 , A61K39/00 , A61K39/12 , A61K39/385 , A61K47/646 , A61K2039/54 , A61K2039/541 , A61K2039/542 , A61K2039/544 , A61K2039/60 , A61K2039/6093 , C12N7/00 , C12N2760/16034 , C12N2760/16122 , C12N2760/16134 , Y02A50/464
摘要: The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
摘要翻译: 本发明提供一种适用于制备药学上可接受的碳氟化合物连接的肽制剂的含水酸性制剂,所述含水制剂包含第一碳氟化合物连接的肽,其中:与所述碳氟化合物连接的肽为至少20个氨基酸残基 长,包含至少50%的疏水性氨基酸残基,并具有大于或等于7的等电点; 并且氟碳连接的肽存在于胶束中。
-
公开(公告)号:WO2009027688A1
公开(公告)日:2009-03-05
申请号:PCT/GB2008/002930
申请日:2008-08-29
申请人: IMMUNE TARGETING SYSTEMS (ITS) LTD , BONNET, Dominique , BROWN, Carlton, B. , GEORGES, Bertrand , SIZER, Philip, J.
IPC分类号: A61K39/385 , A61K39/145
CPC分类号: A61K47/4833 , A61K39/12 , A61K39/145 , A61K39/21 , A61K39/385 , A61K47/54 , A61K47/58 , A61K47/646 , A61K2039/54 , A61K2039/55511 , A61K2039/60 , A61K2039/6018 , A61K2039/6031 , C07K14/005 , C12N2740/16122 , C12N2740/16134 , C12N2760/16034 , C12N2760/16122 , C12N2760/16222 , C12N2760/16322
摘要: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.
摘要翻译: 本发明涉及用于将流感抗原递送至免疫反应性靶细胞的碳氟载体。 它进一步涉及氟碳载体 - 流感抗原构建体,以及在动物(包括人)中使用与抗原相关的载体作为疫苗和免疫治疗剂。
-
公开(公告)号:WO2015082905A1
公开(公告)日:2015-06-11
申请号:PCT/GB2014/053577
申请日:2014-12-02
发明人: GEORGES, Bertrand
CPC分类号: A61K47/646
摘要: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
摘要翻译: 本申请涉及包含免疫刺激部分和肽部分的免疫刺激化合物。 肽部分不是疾病相关的免疫原。 此外,肽部分具有其中75%以下的氨基酸残基为疏水性和/或等电点为5以上的氨基酸序列。 本发明的化合物解决了导致不希望的副作用的免疫刺激剂的全身分布问题。 发明人已经发现免疫刺激剂的物理化学性质可以通过与肽的共价连接来控制。 可以通过引入附加特征以有用的方式修饰其他物理化学性质。
-
-
-